spacer
home > epc > autumn 2006 > paediatric developmental disabilities – getting research right
PUBLICATIONS
European Pharmaceutical Contractor

Paediatric Developmental Disabilities – Getting Research Right

Targeted education can facilitate interest in clinical research participation – Kathleen Drennan and Beth Koch of Iris Global Clinical Trials Solutions give a new insight into the advantages of qualitative market research in ASD

Recent experience has shown that targeted education directed towards parents/caregivers can facilitate interest and participation in autism spectrum disorder (ASD) research. The opportunity to speak with this audience about their children’s ASD elicited valuable feelings regarding the condition and available treatments, and can be an important part of central planning in ASD research.

ASD has recently gained considerable attention at local, national and global levels. Diagnoses of ASD are increasing and though the reason for the increase may be unclear, even controversial, research on the condition, as well as possible treatment options, have become a growing interest for the medical and research communities.

ASD is a group of developmental disabilities caused by abnormalities in the brain, which based on prevalence statistics from the National Institutes of Health (2004) and the Centers for Disease Control and Prevention (2001), affects one in every 166 births (1). Children with ASD exhibit problems along a spectrum of symptoms, including social interaction, verbal and non-verbal communication, and repetitive behaviours or interests (2), which begin in early childhood and last throughout their lives (3). No two people with ASD have the exact same symptoms and their ability levels vary from mentally gifted to mentally challenged (3). ASD occurs in all racial, ethnic and socio-economic groups (3) and is five times more likely to occur in boys than girls (4).

The cause of ASD is still unknown and there is no cure, only treatment. Treatments include support and facilitation, behaviour modification, educational therapy and pharmaceuticals; usually neurologics, already marketed for other indications. New medications for treatment of these behavioural disorders are currently being evaluated.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

Banner of CRS on Samedan
spacer
Drawing from 25 years’ experience in pharmaceutical research and clinical trial development, Kathleen Drennan has implemented a system of integrated services and tools that offers significant opportunities in trial acceleration, pre-and post-marketing, and brand optimisation. Her expertise in patient recruitment, retention and site-related services are long recognised in the industry. Currently Senior Vice President and Managing Director of Iris Global Clinical Trial Solutions, a division of Corbett Accel Healthcare Group, she is a founding member of the Society for Women’s Health Research and resides on the Board of Directors. Kathleen also presides as Editor-in-Chief for Elsevier’s journal, Contemporary Clinical Trials.

Beth Koch is a Project Manager for Iris Global Clinical Trial Solutions, where she runs projects that focus primarily on patient recruitment and retention, and site support. She also serves as Managing Editor for Contemporary Clinical Trials. Beth gained a BA in Interpersonal Communications from Bowling Green State University, where she later obtained a masters in Scientific and Technical Communication.

spacer
Kathleen Drennan
spacer
spacer
spacer
Beth Koch
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

6th European Forum for Qualified Person for Pharmacovigilance (QPPV)

24-26 April 2012, London, UK

This event is for European qualified persons for pharmacovigilance; deputy qualified persons; senior pharmacovigilance regulators and inspectors; CROs and consultants providing QPPV services; and national responsible persons for pharmacovigilance.
More info >>

 
News and Press Releases

Firstan Ltd are first to achieve the new Pharmaceutical PS9000:2011 quality standard

Firstan Ltd, the UK’s leading independently owned Pharmaceutical and Food Carton producer have become the first UK Packaging company to achieve the new Pharmaceutical PS9000:2011 quality standard for its Healthcare Division. This standard was published in September 2011 in consultation with industry suppliers, pharmaceutical companies and other stakeholder organisations. Firstan have held the Pharmaceutical accreditation for almost 20 years.  
More info >>

 

 

Buy Atrovent Online no prescription Buy Symbicort Online no prescription Buy Flovent Online no prescription Buy Flonase Online no prescription Buy Rhinocort Online no prescription Buy Allegra Online no prescription Buy Advair Online no prescription Buy Combivent Online no prescription Buy Astelin Online no prescription Buy Spiriva Online no prescription Buy Ventolin Online no prescription
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement
.